A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia

  • End date
    Mar 12, 2022
  • participants needed
  • sponsor
    Teva Branded Pharmaceutical Products R&D, Inc.
Updated on 19 September 2021
Teva U.S. Medical Information
Primary Contact
Teva Investigational Site 14180 (9.3 mi away) Contact
+44 other location
body mass index
sham treatment


The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously in reducing pain in adult patients with FM. A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered subcutaneously in adult patients with FM.

The total duration of patient participation in the study is planned to be 21 weeks, consisting of a screening period of up to 5 weeks (ranging from 17 to 35 days), and a double-blind treatment period of 16 weeks.

Condition Fibromyalgia, Myofascial Pain Syndrome, fibro
Treatment Placebo, Fremanezumab - Dose A, Fremanezumab - Dose B
Clinical Study IdentifierNCT03965091
SponsorTeva Branded Pharmaceutical Products R&D, Inc.
Last Modified on19 September 2021


Yes No Not Sure

Inclusion Criteria

approved for study participation by the Fibromyalgia Eligibility Review Committee
body mass index of 18.5 to 45 kg/m2 and a body weight 45 kg
agree to use only acetaminophen as rescue medication for FM-related pain (up to 1000 mg per dose and not to exceed 3000 mg/day for any indication throughout the study period)
non-pharmacologic interventions (including normal daily exercise routines, chiropractic care, physical therapy, psychotherapy, and massage therapy) are unchanged for a minimum of 30 days prior to screening and will remain unchanged throughout the study
agree to maintain a usual and unchanged physical exercise regimen
must be of nonchildbearing potential or , defined as
women surgically sterile by documented complete hysterectomy, bilateral oophorectomy, or
bitubal ligations or confirmed to be postmenopausal (at least 1 year since last menstrual period) and
menopausal women confirmed by a follicle-stimulating hormone >35 U/L
men surgically sterile by documented vasectomy OR
If of childbearing potential, patients must meet any of the following
must use highly effective contraception method (Appendix G) with their partners during the entire study period and for 5 months after the last dose of the IMP
sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period
female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (-HCG) pregnancy test at screening (confirmed by urine dipstick -HCG pregnancy test at baseline)
must agree not to participate in another interventional study from the screening period through the EOS Visit o Additional criteria apply, please contact the investigator for more information

Exclusion Criteria

unable or unwilling to discontinue/washout of prohibited medications
ongoing pain that would confound or interfere with the assessment of the patient's FM pain or require excluded therapies during the patient's participation in this study
surgery planned during the study period
receiving prophylactic treatment for migraine-related disorders, including topiramate, valproic acid, onabotulinumtoxinA, amitriptyline, and nortriptyline
known history of clinically significant or unstable hematologic, cardiac, or thromboembolic events
known history of suicide attempt, suicidal behavior, or suicidal ideation within the last 12 months
lifetime history of any psychotic and/or bipolar disorder
current, untreated, moderate or severe major depressive disorder and/or anxiety
known history of hypersensitivity reactions to injected proteins, including mAbs and animal venoms, or a history of Stevens-Johnson Syndrome/toxic epidermal necrolysis syndrome o Additional criteria apply, please contact the investigator for more information
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note